Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
Marzia Fronza, Lorena Lorefice, Jessica Frau, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 1993-2004
Open Access | Times Cited: 25

Showing 25 citing articles:

Structural insights into sphingosine-1-phosphate receptor activation
Leiye Yu, Licong He, Bing Siang Gan, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 16
Open Access | Times Cited: 43
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Pablo A. Olivera, Axel Dignaß, Marla C. Dubinsky, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 8, pp. 1270-1280
Open Access | Times Cited: 6
An unraveled mystery: What's the role of brain sphingolipids in neurodegenerative and psychiatric disorders
Xintian Bie, Min Zhang, Qingyu Wang, et al.
Neurobiology of Disease (2025) Vol. 207, pp. 106852-106852
Open Access
Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis
Fan Jiang, Fenghe Zhang, Yue Su, et al.
Heliyon (2024) Vol. 10, Iss. 11, pp. e31744-e31744
Open Access | Times Cited: 4
Bioinformatics Exploration of the Therapeutic Potential of Lotus Seed Compounds in Multiple Sclerosis: A Network Analysis of c‐Jun Pathway
Rapuru Rushendran, Ankul Singh S, Rukaiah Fatma Begum, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Multiple Sclerosis: Therapeutic Strategies on the Horizon
Ramya Talanki Manjunatha, Salma Habib, Sai Lahari Sangaraju, et al.
Cureus (2022)
Open Access | Times Cited: 20
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)
Lindsey Sattler, Stephen B. Hanauer, Lisa Malter
Current Gastroenterology Reports (2021) Vol. 23, Iss. 12
Closed Access | Times Cited: 23
S1P/S1PR signaling pathway advancements in autoimmune diseases
Jianbin Li, Yiping Huang, Yueqin Zhang, et al.
Biomolecules and Biomedicine (2023)
Open Access | Times Cited: 9
Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage
Saad Khan, Kayla F. Goliwas, Jessy S. Deshane
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 18
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center
Nathaniel A. Cohen, David Choi, Tenzin Choden, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 9, pp. 2407-2409.e2
Open Access | Times Cited: 13
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center
Nathaniel A. Cohen, David Choi, Nicole Garcia, et al.
Digestive Diseases and Sciences (2023) Vol. 69, Iss. 2, pp. 579-587
Closed Access | Times Cited: 6
Possibilities and limitations of computer assisted chiral HPLC method development for ozanimod on polysaccharide based chiral stationary phases
Elek Ferencz, Zoltán‐István Szabó, Arnold Zöldhegyi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review
Vincenzo Carlomagno, Massimiliano Mirabella, Matteo Lucchini
Bioengineering (2023) Vol. 10, Iss. 7, pp. 848-848
Open Access | Times Cited: 4
Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases
Anna Kofla-Dłubacz, Katarzyna Akutko, Elżbieta Krzesiek, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 994-994
Open Access | Times Cited: 7
An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis
Catherine Rowan, Ryan C. Ungaro, Saurabh Mehandru, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 8, pp. 893-904
Closed Access | Times Cited: 5
Efforts Towards Repurposing of Antioxidant Drugs and Active Compounds for Multiple Sclerosis Control
Panagiotis Theodosis‐Nobelos, Eleni A. Rekka
Neurochemical Research (2022) Vol. 48, Iss. 3, pp. 725-744
Closed Access | Times Cited: 5
Regulation of Vascular Endothelial Barrier Integrity and Function by Lipid-Derived Mediators
Panfeng Fu, Ramaswamy Ramchandran, Steven M. Dudek, et al.
Springer eBooks (2022), pp. 445-484
Closed Access | Times Cited: 3
Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple Sclerosis
Caroline Ruetsch-Chelli, Darin T. Okuda, Fanny Rocher, et al.
Neurology and Therapy (2022) Vol. 12, Iss. 1, pp. 289-302
Open Access | Times Cited: 3
Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies
Vipul Jairath, Waqqas Afif, Brian Bressler, et al.
Journal of the Canadian Association of Gastroenterology (2024) Vol. 7, Iss. 4, pp. 282-289
Open Access
Nanocarriers and Nano Drug Delivery Therapy in Neuro Diseases
Palak Rana, Gursharan Kaur, Aleena James Chirayimmel, et al.
(2024), pp. 219-251
Closed Access
Computer-assisted chiral HPLC method development for ozanimod on polysaccharide- based chiral stationary phases: possibilities and limitations
Elek Ferencz, Zoltán‐István Szabó, Arnold Zöldhegyi, et al.
Research Square (Research Square) (2024)
Open Access
Synthesis and Clinical Application of New Drugs Approved by NMPA in 2023
Lijuan Xie, Yingying Wang, Kunyu Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117181-117181
Closed Access
Lessons from immunotherapies in multiple sclerosis
Marianna Gabriella Rispoli, Maria D’Apolito, Valeria Pozzilli, et al.
Handbook of clinical neurology (2023), pp. 293-311
Closed Access | Times Cited: 1
A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis
Roni Aoun, Stephen B. Hanauer
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 5, pp. 411-423
Closed Access | Times Cited: 2
Structural Insights into Sphingosine-1-phosphate Receptor Activation
Leiye Yu, Licong He, Bing Siang Gan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top